Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market: Epidemiology, Therapies, Companies, DelveInsight | Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli L

Metastatic Castration-Resistant Prostate Cancer (mCRPC) therapies, such as JEVTANA (Cabazitaxel), XOFIGO (radium-223), Opevesostat (MK-5684; ODM-208), TRUQAP (capivasertib, AZD 5363), and others, are expected to boost the Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market in the upcoming years.

DelveInsight has launched a new report on "Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Metastatic Castration-Resistant Prostate Cancer (mCRPC), historical and forecasted epidemiology as well as the Metastatic Castration-Resistant Prostate Cancer (mCRPC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Metastatic Castration-Resistant Prostate Cancer (mCRPC) market report @ https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Report:

In 2023, the total market size for metastatic castration-resistant prostate cancer (mCRPC) across the 7 major markets (7MM) was estimated at approximately USD 6.8 billion. This market is projected to grow steadily through 2034, driven by the increasing incidence of prostate cancer in developing regions-attributable to lifestyle changes, aging demographics, and improved healthcare access.
In March 2025, the FDA broadened the approved use of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan), developed by Novartis, to include adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously received androgen receptor pathway inhibitor (ARPI) therapy and are eligible to postpone taxane-based chemotherapy.
Novartis confirmed the FDA's approval of this expanded indication, allowing Pluvicto to be used earlier in the treatment course for appropriate mCRPC patients.
The United States led the mCRPC market in 2023, accounting for nearly 64% of the total therapeutic market share in the 7MM.
The current mCRPC treatment landscape offers a broad array of therapeutic options, including PARP inhibitors, androgen receptor inhibitors, CYP17 inhibitors, microtubule inhibitors, ionizing radiation therapies, and others used across various lines of treatment.
Of the two primary forms of metastatic prostate cancer-mCSPC and mCRPC-the latter was more prevalent in the 7MM in 2023.
Recent approvals in 2023 include AKEEGA (a combination of niraparib and abiraterone acetate) and the pairing of TALZENNA (talazoparib) with XTANDI (enzalutamide) for mCRPC patients. Additional approved therapies in recent years include XTANDI, PROVENGE, JEVTANA, ZYTIGA, LYNPARZA, and PLUVICTO. Notably, Novartis' PLUVICTO, a radioligand therapy approved in 2022, has generated substantial revenue in the third-line treatment setting.
Among available treatments, XTANDI and abiraterone acetate remain the dominant androgen deprivation therapies (ADTs), especially in first- and second-line treatment, with XTANDI alone holding approximately 41% of the mCRPC market share in the 7MM in 2023.
Numerous pharmaceutical companies are actively advancing the mCRPC pipeline, including Curium, Bristol-Myers Squibb, Merck and Orion, Pfizer, Merus, Zenith Epigenetics, MacroGenics, Laekna Therapeutics, Ipsen, AstraZeneca, Telix International, ESSA Pharma, Arvinas, Novartis, Lantheus, Eli Lilly/POINT Biopharma, Xencor, and Promontory Therapeutics.
The mCRPC pipeline is particularly robust across all lines of therapy. In the first-line setting, notable candidates include Merck's Opevesostat, ESSA Pharma's Masofaniten, and Tavanta's TAVT-45.
In the second-line setting, CABOMETYX is expected to be among the first emerging therapies to gain approval.
For third-line and beyond, promising candidates include Lantheus/Eli Lilly-POINT Biopharma's 177Lu-PNT2002, AstraZeneca's FPI-2265 (actinium-225 PSMA-targeted radio-conjugate), and the ARV-766 PROTAC AR degrader from Arvinas and Novartis.
Overall, the mCRPC market is poised for substantial expansion during the forecast period, with growth fueled by the continued uptake of approved therapies, label expansions, and the entry of new, innovative treatment options.
In 2023, there were an estimated 7,279,500 prevalent cases of prostate cancer across the 7 major markets (7MM). This number is projected to increase over the forecast period (2024-2034), driven by an aging population and improvements in diagnostic technologies.
In the United States alone, the five-year prevalence of prostate cancer was approximately 1,093,300 cases in 2023.
Key Metastatic Castration-Resistant Prostate Cancer (mCRPC) companies such as Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others are evaluating new drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) to improve the treatment landscape.
Promising Metastatic Castration-Resistant Prostate Cancer (mCRPC) therapies include JEVTANA (Cabazitaxel), XOFIGO (radium-223), Opevesostat (MK-5684; ODM-208), TRUQAP (capivasertib, AZD 5363), and others.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview

Prostate cancer is a type of cancer that develops in the prostate gland. It typically progresses slowly and often remains localized to the prostate in its early stages, where it may not pose significant health risks. While it is most commonly diagnosed in men aged 50-64 and those over 65, it can also affect younger men under 50.

Common symptoms of prostate adenocarcinoma include blood in the semen, a frequent need to urinate, and discomfort or pain during urination. These symptoms usually don't become noticeable until the enlarged prostate starts to press on the urethra-the tube responsible for carrying urine from the bladder out.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook

Current treatment options for castration-resistant prostate cancer (CRPC), in addition to androgen deprivation therapy (ADT), include sipuleucel-T, chemotherapy (with docetaxel as a first-line option or cabazitaxel for patients previously treated with docetaxel), abiraterone acetate, enzalutamide, PARP inhibitors such as olaparib and rucaparib (for patients with DNA damage repair gene mutations), and radium-223 for those with bone metastases. Despite these options, metastatic CRPC (mCRPC) remains a life-threatening condition, highlighting the ongoing need for more effective therapeutic strategies to improve patient outcomes.

Until 2010, docetaxel was the only FDA-approved drug shown to extend survival in mCRPC when used with prednisone, receiving approval in 2004. For many years, patients who did not respond to docetaxel lacked further approved treatment options. However, the therapeutic landscape has significantly evolved with the approval of several agents, including PROVENGE, JEVTANA, ZYTIGA, XTANDI, LYNPARZA, TALZENNA, and AKEEGA, all now approved in the U.S. for mCRPC.

The emergence of PARP inhibitors has notably advanced personalized treatment for mCRPC, particularly in patients with mutations in DNA damage repair genes. Key approvals in 2023 included AKEEGA (Janssen), TALZENNA (Pfizer/Astellas Pharma), and LYNPARZA (AstraZeneca/Merck, in combination therapies), all strengthening the precision medicine approach in prostate cancer care.

Additionally, PLUVICTO (Novartis), a PSMA-targeted radioligand therapy, gained FDA approval in 2022 for treating PSMA-positive mCRPC, offering a novel mechanism of action and expanding the range of available therapies.

Currently, numerous biopharmaceutical companies are conducting clinical trials to explore both new and existing treatments for mCRPC. Companies actively involved include Curium, Bristol-Myers Squibb, Merck and Orion, Pfizer, Merus, Zenith Epigenetics, MacroGenics, Laekna Therapeutics, Ipsen, AstraZeneca, Telix International, ESSA Pharma, Arvinas, Novartis, Lantheus, Eli Lilly/POINT Biopharma, Xencor, and Promontory Therapeutics, all aiming to improve mCRPC management across different lines of therapy.

Discover how the Metastatic Castration-Resistant Prostate Cancer (mCRPC) market is rising in the coming years @ https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Marketed Metastatic Castration-Resistant Prostate Cancer Drugs

JEVTANA (Cabazitaxel): Sanofi
XOFIGO (radium-223): Bayer

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Drugs
Opevesostat (MK-5684; ODM-208): Merck and Orion
TRUQAP (capivasertib, AZD 5363): AstraZeneca

Scope of the Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Metastatic Castration-Resistant Prostate Cancer (mCRPC) Companies: Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapies: JEVTANA (Cabazitaxel), XOFIGO (radium-223), Opevesostat (MK-5684; ODM-208), TRUQAP (capivasertib, AZD 5363), and others.
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapeutic Assessment: Metastatic Castration-Resistant Prostate Cancer (mCRPC) current marketed and Metastatic Castration-Resistant Prostate Cancer (mCRPC) emerging therapies
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Dynamics: Metastatic Castration-Resistant Prostate Cancer (mCRPC) market drivers and Metastatic Castration-Resistant Prostate Cancer (mCRPC) market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Unmet Needs, KOL's views, Analyst's views, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Access and Reimbursement

To know what's more in our Metastatic Castration-Resistant Prostate Cancer (mCRPC) report, visit https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Report:
The Metastatic Castration-Resistant Prostate Cancer (mCRPC) market report covers a descriptive overview and comprehensive insight of the Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidemiology and Metastatic Castration-Resistant Prostate Cancer (mCRPC) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Metastatic Castration-Resistant Prostate Cancer (mCRPC) market report provides insights into the current and emerging therapies.
The Metastatic Castration-Resistant Prostate Cancer (mCRPC) market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Metastatic Castration-Resistant Prostate Cancer (mCRPC) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Metastatic Castration-Resistant Prostate Cancer (mCRPC) market.

Got queries? Click here to know more about the Metastatic Castration-Resistant Prostate Cancer (mCRPC) market Landscape https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patient Share (%) Overview at a Glance
5. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Overview at a Glance
6. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Disease Background and Overview
7. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidemiology and Patient Population
8. Country-Specific Patient Population of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
9. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Current Treatment and Medical Practices
10. Unmet Needs
11. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapies
12. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook
13. Country-Wise Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Outlook 2034 https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pipeline Insights, DelveInsight

"Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Metastatic Castration-Resistant Prostate Cancer (mCRPC) market. A detailed picture of the Metastatic Castration-Resistant Prostate Cancer (mCRPC) pipeline landscape is provided, which includes the disease overview and Metastatic Castration-Resistant Prostate Cancer (mCRPC) treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.